RecruitingPhase 1NCT03240328
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
Sponsor
Guangzhou 8th People's Hospital
Enrollment
40 participants
Start Date
Oct 4, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria5
- HIV infection confirmed.
- Receiving cART more than 12 months.
- HIV viral-load \< 50 copies/ml and CD4 cell count more than 350 cells/ul.
- Without serious liver, heart, liver and kidney diseases.
- The subjects know about the study and volunteer to attend the research and sign the informed consent.
Exclusion Criteria6
- With active HBV or HCV infection, or serious opportunistic infections.
- With serious chronic disease such like diabetes, the mental illness,et al
- History of suffering from pancreatitis during cART.
- Pregnant or breast-fed.
- With poor adherence.
- Unable to complete follow up.
Interventions
BIOLOGICALCAR-T cells
HIV-1 specific chimeric antigen receptor cells
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03240328
Related Trials
Appalachian Partnership to Reduce Disparities (Aim 2)
NCT043784391 location
MyPEEPS LITE Trial
NCT067416312 locations
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
NCT067416181 location
An Integrated Intervention Using a Pill Ingestible Sensor System
NCT064805781 location
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study
NCT072987851 location